Challenges in Interpreting Thyroid Stimulating Hormone Results in the Diagnosis of Thyroid Dysfunction
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 9 of the 87 sources its claims cite were checked for support.
Abstract
The pituitary hormone, thyrotropin (TSH), is regarded as the primary biomarker for evaluating thyroid function and is useful in guiding treatment with levothyroxine for patients with hypothyroidism. The amplified response of TSH to slight changes in thyroid hormone levels provides a large and easily measured signal in the routine care setting. Laboratories provide reference ranges with upper and lower cutoffs for TSH to define normal thyroid function. The upper limit of the range, used to diagnose subclinical (mild) hypothyroidism, is itself a matter for debate, with authoritative guidelines recommending treatment to within the lower half of the range. Concomitant diseases, medications, supplements, age, gender, ethnicity, iodine status, time of day, time of year, autoantibodies, heterophilic antibodies, smoking, and other factors influence the level of TSH, or the performance of current TSH assays. The long-term prognostic implications of small deviations of TSH from the reference range are unclear. Correction of TSH to within the reference range does not always bring thyroid and other biomarkers into range and will not always resolve the patient’s symptoms. Overt hypothyroidism requires intervention with levothyroxine. It remains important that physicians managing a patient with symptoms suggestive of thyroid disease consider all of the patient’s relevant disease, lifestyle, and other factors before intervening on the basis of a marginally raised TSH level alone. Finally, these limitations of TSH testing mitigate against screening the population for the undoubtedly substantial prevalence of undiagnosed thyroid disease, until appropriately designed randomised trials have quantified the benefits and harms from this approach.
Overview
CoChat Summary
TL;DR
This narrative review argues that TSH is the primary biomarker for thyroid dysfunction but that its interpretation is complicated by demographic, disease, medication, assay, and temporal factors, and by uncertain reference-range cutoffs. It concludes that clinicians should not treat a marginally raised TSH alone and that population screening lacks sufficient evidence.
Key findings
- Guidelines cite an adult TSH reference and therapeutic target range of 0.4–4.0 mIU/mL; subclinical hypothyroidism is TSH above the reference with normal thyroid hormones, and NICE recommends controlling TSH to 0.4–2.5 mIU/L for most people with treated subclinical hypothyroidism.
- TSH upper reference limits vary with age: in about 150,000 thyroid antibody-negative people, the 97.5th percentile increased from 3.98 mIU/L at age 31–40 to 5.94 mIU/L at age >90 years; higher TSH is also seen in women and in some ethnic groups.
- Many factors affect TSH or TSH assays, including medications/supplements (e.g., metformin lowers TSH), assay interference estimated in almost 1% of all thyroid function tests, macro-TSH, heterophilic antibodies, biotin, diurnal/circannual variation, pregnancy, obesity, smoking, and endocrine disruptors.
- Small TSH elevations may resolve: 37/40 people with subclinical hypothyroidism (TSH >5 mIU/L) reverted to normal over 5 years; undiagnosed thyroid disease prevalence was about 6% in NHANES III and about 5% undiagnosed hypothyroidism and 2% undiagnosed hyperthyroidism in a European meta-analysis, but screening is not supported by current evidence.
Methods
- Narrative review summarizing the evidence-based rationale for current thyroid testing and common pitfalls in interpreting TSH results.
- No primary data or systematic sample; it draws on published studies, guidelines, and reviews, including large population cohorts and meta-analyses.
- Main analysis is a qualitative synthesis of factors affecting TSH and reference ranges; no meta-analysis or formal risk-of-bias assessment is described.
Limitations
- The paper states that the upper TSH cutoff best predicting prognosis remains uncertain, the long-term prognostic implications of small TSH deviations are unclear, evidence is insufficient for population screening and for individualized/optimal TSH ranges, and easily measurable biomarkers of tissue thyroid hormone status are needed.
- Evident from the text: as a narrative review, it does not report a systematic search strategy, study selection, or quality appraisal, and it presents no primary data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Overview of common factors that can produce an aberrant TSH test. aMetformin reduces serum TSH in people with overt or subclinical hypothyroidism and in euthyroid individuals with high normal baseline TSH levels (see refs [31] and [32]; see text for other references). HAMA: human anti-mouse antibody; RF: rheumatoid factor; TSH: thyrotropin.](https://figures.cochat.ai/paper-figures/4af47df45eb7466cb0b63d0edfc89b0a/challenges-in-interpreting-thyroid-stimulating-hormone-results-in-the-diagnosis-figure-1.jpg)
Verification
Claims the paper makes
8 Valid · 4 Not valid · 56 Not checked · 17 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Treatment with levothyroxine has been shown to influence an individual's set point for thyroid function, with higher FT4 and lower FT3, despite a lower TSH level compared with untreated patients [42].”
§ Challenges in Interpreting Thyroid Stimulating Hormone Results in the Diagnosis of Thyroid Dysfunction > 3. Serum TSH as the Principal Diagnostic Marker of Systemic Thyroid Status > 3.2. Limitations of TSH as a Diagnostic Marker of Thyroid Function
What the sources say
- Supportedcites [42] Hoermann R. Midgley J. E. M. Giacobino A. Homeostatic equilibria between free thyroid hormones and pituitary thyrotropin are modulated by various influences including age, body mass index and treatment Clinical Endocrinology 2014 81 6 907 915 10.1111/cen.12527 2-s2.0-84912530723 24953754 source
The Influence of L-T4 treatment section reports that treated patients with autoimmune thyroiditis had lower FT3 and higher TSH-adjusted FT4 than untreated patients; the Discussion also notes lower TSH in the treated group. The paper describes these differences as modified homeostatic equilibria, supporting the paraphrase about a changed thyroid-function set point. Page numbers were not available in our copy. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Biotin, antistreptavidin antibodies, antiruthenium antibodies, and thyroid hormone autoantibodies provide other sources of interference with the TSH test that may lead to an aberrant result [36].”
§ Challenges in Interpreting Thyroid Stimulating Hormone Results in the Diagnosis of Thyroid Dysfunction > 3. Serum TSH as the Principal Diagnostic Marker of Systemic Thyroid Status > 3.2. Limitations of TSH as a Diagnostic Marker of Thyroid Function
What the sources say
- Partly supportedcites [36] Favresse J. Burlacu M.-C. Maiter D. Gruson D. Interferences with thyroid function immunoassays: clinical implications and detection algorithm Endocrine Reviews 2018 39 5 830 850 10.1210/er.2018-00119 2-s2.0-85054467081 29982406 sourceExperimental — accuracy not yet measured
The Abstract (our copy) names exactly these agents among the six main interferences affecting TSH, FT4 and FT3 measurements, and the body documents TSH-specific distortion for three of them: biotin causing 'falsely low TSH levels' (Biotin Interference), anti-streptavidin antibodies with 'TSH ↓' (Table 3 / Anti-Streptavidin Antibody Interference), and anti-Ru antibodies that 'may also induce elevated TSH' (Anti-Ru Interference). The fourth item is not supported for TSH: the TH Autoantibody Interference section states that anti-T3/anti-T4 THAAbs are the ones that interfere in thyroid hormone measurements and that 'In patients known to exhibit THAAbs, TSH measurement provides the most reliable thyroid function test' — i.e. THAAbs are presented as an interference with FT3/FT4, not with the TSH assay. The hedged 'may lead to an aberrant result' matches the source's own wording. (LLM, conf=0.78)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Numerous concurrent medications and supplements can interfere with thyroid function tests (summarised in Figure 1) [27, 28].”
§ Challenges in Interpreting Thyroid Stimulating Hormone Results in the Diagnosis of Thyroid Dysfunction > 3. Serum TSH as the Principal Diagnostic Marker of Systemic Thyroid Status > 3.2. Limitations of TSH as a Diagnostic Marker of Thyroid Function
What the sources say
- Not checked yetcites [27] Faix J. D. Thienpoint L. M. Thyroid-Stimulating Hormone. Why Efforts to Harmonize Testing are Critical to Patient Care 2013 Washington, DC, USA American Association of Clinical Chemists https://www.aacc.org/publications/cln/articles/2013/may/tsh-harmonization
- Partly supportedcites [28] Koulouri O. Moran C. Halsall D. Chatterjee K. Gurnell M. Pitfalls in the measurement and interpretation of thyroid function tests Best Practice & Research Clinical Endocrinology & Metabolism 2013 27 6 745 762 10.1016/j.beem.2013.10.003 2-s2.0-84888313903 24275187 PMC3857600 sourceExperimental — accuracy not yet measured
The 'Drug therapy' section of Koulouri et al. (2013) supports the medications half of the claim: it opens 'An array of commonly prescribed drugs may result in altered thyroid function/status, either by modulating the HPT axis itself, or through downstream effects on thyroid hormone transport or metabolism', and goes on to list numerous agents (oral oestrogen, raloxifene, tamoxifen, mitotane, fluorouracil, methadone, heroin, androgens, glucocorticoids, nicotinic acid for TBG changes; furosemide, aspirin, NSAIDs, phenytoin and heparin for T4/T3 displacement distorting FT4/FT3 measurement), with Table 3 cataloguing drugs altering pituitary TSH or thyroidal T4/T3 secretion. However, no passage of our copy addresses supplements: searches for 'supplements', 'biotin' and 'nutritional' returned only these drug/assay-interference passages and reference-list entries, so the supplement component of the claim is not attributable to this source (it presumably rests on the companion citation [28]). (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Importantly, a halving of circulating T4 is accompanied by up to a 100-fold increase in serum TSH.”
§ Challenges in Interpreting Thyroid Stimulating Hormone Results in the Diagnosis of Thyroid Dysfunction > 2. Overview of TSH and Relationship with Thyroid Hormones
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“A diurnal variation exists for TSH levels in euthyroid and hypothyroid patients (treated or untreated), with lower values in the daytime [44, 45].”
§ Challenges in Interpreting Thyroid Stimulating Hormone Results in the Diagnosis of Thyroid Dysfunction > 3. Serum TSH as the Principal Diagnostic Marker of Systemic Thyroid Status > 3.2. Limitations of TSH as a Diagnostic Marker of Thyroid Function
What the sources say
- Not checked yetcites [44] Warade J. Pandey A. Diurnal variation of TSH: factor affecting interpretation of test Journal of Pharmaceutical and Biomedical Analysis 2014 04 9 776 780
- Not checked yetcites [45] Weeke J. Laurberg P. Diurnal TSH variations in hypothyroidism The Journal of Clinical Endocrinology & Metabolism 1976 43 1 32 37 10.1210/jcem-43-1-32 2-s2.0-0017099609 985825 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
22 more claims
Create a free account to see all 85 claims and to verify the 78 references still open.
- It may state two separate claims as one. 32
- Probably not a substantial claim. 36
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, serum TSH levels may be influenced by numerous factors, such as ethnicity, gender, age [1,2,22] and pregnancy; for the latter specific reference interval related to age of gestation are required [23,24].”
The cited source says what the claim attributes to it.
In the citing paper
“Considering the diurnal variation of especially TSH [22]”
In the citing paper
“The current TSH reference interval, especially the upper limit, is still under debate [22,25,26], due to the possible high prevalence of subclinical thyroid diseases that makes it difficult to identify truly healthy subjects.”
In the citing paper
“Mean TSH was lower in those who received T3 vs.only LT4 (1.1 vs. 2.1 mIU/L), though both mean values were within the usual reference range for TSH 10 .”
From A review of the safety of triiodothyronine in combination with levothyroxine for the management of hypothyroidism (2024) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Challenges in Interpreting Thyroid Stimulating Hormone Results in the Diagnosis of Thyroid Dysfunction > 3. Serum TSH as the Principal Diagnostic Marker of Systemic Thyroid Status > 3.1. Evolution of the TSH Test
“Guidelines cite a reference and therapeutic target range for TSH to define normal thyroid function in adults at 0.4–4.0 mIU/mL [9].”
§ Challenges in Interpreting Thyroid Stimulating Hormone Results in the Diagnosis of Thyroid Dysfunction > 3. Serum TSH as the Principal Diagnostic Marker of Systemic Thyroid Status > 3.2. Limitations of TSH as a Diagnostic Marker of Thyroid Function
“Guidance from the UK National Institute for Health and Care Excellence (NICE) recommends controlling TSH to the lower half of the reference range (0.4–2.5 mIU/L) for most people with subclinical hypothyroidism who require treatment [8].”
Citations
Cites
Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279 · cited 4×
“non-Hispanic black orMexican American subjects [24].”
BackgroundResultInfluentialStagnaro-Green, A., Abalovich, M., Alexander, E., Azizi, F., Mestman, J., Negro, R., Nixon, A., Pearce, E. N., Soldin, O. P., Sullivan, S., et al. (2011) · Thyroid · doi:10.1089/thy.2011.0087 · Cited by 2,942
Alexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., et al. (2017) · Thyroid® · doi:10.1089/thy.2016.0457 · Cited by 2,731 · cited 1×
“Current guidelines for the management of thyroid disease accept the need for a lower upper limit of the reference range during different stages of pregnancy, but differences between populations in the magnitude of the effect of pregnancy on thyroid hormone levels have been observed [8, 48].”
BackgroundThyroid Hormone Regulation of Metabolism
Mullur, R., Liu, Y.-Y., & Brent, G. A. (2014) · Physiological Reviews · doi:10.1152/physrev.00030.2013 · Cited by 2,421
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · cited 3×
“(e management of overt thyroid dysfunction is not disputed, and there is widespread agreement that this condition should be treated [8, 9].”
BackgroundGlobal epidemiology of hyperthyroidism and hypothyroidism
Taylor, P. N., Albrecht, D., Scholz, A., Gutierrez-Buey, G., Lazarus, J. H., Dayan, C. M., & Okosieme, O. E. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.18 · Cited by 1,552
2013 ETA Guideline: Management of Subclinical Hypothyroidism
Pearce, S. H. S., Brabant, G., Duntas, L. H., Monzani, F., Peeters, R. P., Razvi, S., & Wemeau, J.-L. (2013) · European Thyroid Journal · doi:10.1159/000356507 · Cited by 877
Self-citationThe Incidence and Prevalence of Thyroid Dysfunction in Europe: A Meta-Analysis
Garmendia Madariaga, A., Santos Palacios, S., Guillén-Grima, F., & Galofré, J. C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2409 · Cited by 800 · cited 2×
“A meta-analysis of studies from Europe found a high prevalence of undiagnosed hypothyroidism of about 5% and of undiagnosed hyperthyroidism of about 2% [5].”
BackgroundAndersen, S., Pedersen, K. M., Bruun, N. H., & Laurberg, P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8165 · Cited by 686 · cited 1×
“Longitudinal measurement of thyroid hormones in healthy individuals has shown that levels of T3, T4, and FT4 index vary little over time [38].”
BackgroundThe Evidence for a Narrower Thyrotropin Reference Range Is Compelling
Wartofsky, L., & Dickey, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0455 · Cited by 424 · cited 1×
“5mIU/L and people with higher values were likely to have Hashimoto’s thyroiditis or other conditions that increase TSH [56].”
Background
Research works printed but not linked: 4
- Shahid M. A. Sharma S. Physiology, Thyroid Hormone 2019 Treasure Island, FL, USA Stat Pearls https://www.ncbi.nlm.nih.gov/books/NBK500006
- Spencer C. A. De Groot L. J. Chrousos G. Dungan K. Assay of Thyroid Hormones and Related Substances 2017 San Francisco, CA, USA South Dartmouth: MDText.com, Inc. https://www.thyroidmanager.org/chapter/assay-of-thyroid-hormones-and-related-substances3
- Warade J. Pandey A. Diurnal variation of TSH: factor affecting interpretation of test Journal of Pharmaceutical and Biomedical Analysis 2014 04 9 776 780
- Helfand M. Stone M. B. Wallace R. B. Appendix B. Screening for thyroid disease: systematic evidence review Medicare Coverage of Routine Screening for Thyroid Dysfunction. Institute of Medicine (US) Committee on Medicare Coverage of Routine Thyroid Screening 2003 Washington, DC, USA National Academies Press (US) https://www.ncbi.nlm.nih.gov/books/NBK221542/ 25057658
Cited by
Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?
Ettleson, M. D., & Bianco, A. C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa430 · Cited by 75
The role of thyroid function in female and male infertility: a narrative review
Mazzilli, R., Medenica, S., Tommaso, A. M. D., Fabozzi, G., Zamponi, V., Cimadomo, D., Rienzi, L. F., Ubaldi, F. M., Watanabe, M., Faggiano, A., et al. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01883-7 · Cited by 102
“Several studies suggest that fetal exposure to excessive levels of maternal thyroid hormone induces low birth weight, intrauterine growth restriction and stillbirth; furthermore, this condition could be related to seizure and neurobehavioral disorders in the offspring [30, 31].”
Vegan nutrition: a preliminary guide for health professionals
Koeder, C., & Pérez-Cueto, F. J. A. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2107997 · Cited by 80
Urgatz, B., & Razvi, S. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2165811 · Cited by 80
Self-citationOptical Detection of Cancer Cells Using Lab-on-a-Chip
Hernández, L. A. G., Martínez‐Martínez, E., Pazos-Solis, D. M., Aguado-Preciado, J., Dutt, A., Chávez-Ramírez, A. U., Korgel, B. A., Sharma, A. K., & Oza, G. (2023) · Biosensors · doi:10.3390/bios13040439 · Cited by 54
“The early diagnosis of thyroid cancer is crucial, and thyroid-stimulating hormone (TSH) is a widely used biomarker for this purpose [50].”
Background
Metadata
- Authors
- Razvi, S., Bhana, S., & Mrabeti, S.
- Affiliations
- Newcastle University (GB)
- University of the Witwatersrand (ZA)
- Medical Affairs EMEA, Merck Serono Middle East FZ-LLC, Dubai, UAE
- Corresponding author
- Razvi, Salman
- Venue
- Journal of Thyroid Research
- Publisher
- Wiley
- Published
- 2019-09-22
- Volume
- 2019
- Pages
- 1-8
- ISSN
- 2042-0072 (ISSN-L)
- 2090-8067
- PMC
- PMC6778876
- OpenAlex
- W2972101486
- Semantic Scholar
- af972752786d7340b3608677dac4457e01c214eb
- Cited by
- 90
- References
- 63
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 15 · 2023: 14 · 2022: 13 · 2021: 17 · 2020: 10
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Thyroid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- thyroid-stimulating hormone, TSH reference range, subclinical hypothyroidism, hypothyroidism diagnosis, levothyroxine, heterophile antibodies, thyroid autoantibodies, overt hypothyroidism, thyroid screening, thyroid function tests
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Challenges in Interpreting Thyroid Stimulating Hormone Results in the Diagnosis of Thyroid Dysfunction. https://app.cochat.ai/papers/10.1155/2019/4106816
- The paper
- Razvi, S., Bhana, S., & Mrabeti, S. (2019). Challenges in Interpreting Thyroid Stimulating Hormone Results in the Diagnosis of Thyroid Dysfunction. Journal of Thyroid Research. https://doi.org/10.1155/2019/4106816
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.